Ranger Investment Management L.P. Trims Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Ranger Investment Management L.P. lowered its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 2.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 72,476 shares of the company's stock after selling 1,595 shares during the quarter. Medpace accounts for approximately 1.5% of Ranger Investment Management L.P.'s investment portfolio, making the stock its 28th largest position. Ranger Investment Management L.P. owned approximately 0.23% of Medpace worth $24,079,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the business. Lindbrook Capital LLC raised its stake in shares of Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after acquiring an additional 29 shares during the last quarter. HBK Sorce Advisory LLC grew its stake in shares of Medpace by 0.5% in the 4th quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company's stock worth $1,789,000 after acquiring an additional 29 shares in the last quarter. Assetmark Inc. lifted its holdings in Medpace by 20.1% during the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after acquiring an additional 29 shares during the period. Proficio Capital Partners LLC boosted its stake in Medpace by 4.1% in the fourth quarter. Proficio Capital Partners LLC now owns 730 shares of the company's stock valued at $243,000 after acquiring an additional 29 shares during the last quarter. Finally, Schulhoff & Co. Inc. grew its position in shares of Medpace by 1.2% during the 4th quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company's stock valued at $874,000 after acquiring an additional 30 shares during the period. Institutional investors own 77.98% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. TD Cowen lowered Medpace from a "buy" rating to a "hold" rating and set a $328.00 price objective for the company. in a report on Monday. Robert W. Baird lifted their price objective on Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a report on Monday, January 27th. Leerink Partners started coverage on shares of Medpace in a report on Monday, March 24th. They set a "market perform" rating and a $330.00 price objective on the stock. Mizuho reduced their target price on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a research note on Wednesday, April 9th. Finally, Truist Financial dropped their price target on shares of Medpace from $347.00 to $333.00 and set a "hold" rating on the stock in a research note on Thursday. Ten investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Medpace has an average rating of "Hold" and an average target price of $357.50.

Medpace Stock Performance

MEDP traded up $3.19 on Monday, reaching $300.91. The company had a trading volume of 205,637 shares, compared to its average volume of 319,245. Medpace Holdings, Inc. has a 52-week low of $272.00 and a 52-week high of $459.77. The company has a market cap of $9.10 billion, a price-to-earnings ratio of 23.83, a P/E/G ratio of 3.81 and a beta of 1.46. The business has a 50 day simple moving average of $323.58 and a 200 day simple moving average of $334.47.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating analysts' consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.